Nyxoah reported second quarter global net revenue of €7.7 million, a significant increase from €1.3 million in the prior-year period, driven by the ongoing U.S. commercialization of its Genio system. The company posted a net loss of €33.0 million, or €0.578 per share. The U.S. launch showed strong momentum, with revenue reaching €5.2 million, up 22% sequentially from the first quarter.
Key Highlights
- Global net revenue for Q2 2026 was €7.7 million, compared to €1.3 million in Q2 2025, with U.S. revenue contributing €5.2 million.
- The U.S. commercial launch is accelerating, with 89 new accounts activated in the second quarter, bringing the total to 180 active high-volume accounts.
- The patient pipeline grew significantly, with 427 patients actively under prior authorization entering the third quarter, a 77% increase from the start of Q2.
- Nyxoah ended the quarter with a strong cash position of €97.8 million after securing $110 million in financing during the period.